1. Home
  2. LPA vs KZIA Comparison

LPA vs KZIA Comparison

Compare LPA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$2.85

Market Cap

93.9M

Sector

N/A

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$10.99

Market Cap

100.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
KZIA
Founded
2013
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.9M
100.8M
IPO Year
2023
2002

Fundamental Metrics

Financial Performance
Metric
LPA
KZIA
Price
$2.85
$10.99
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
18.6K
198.1K
Earning Date
05-13-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$4.86
52 Week High
$8.08
$17.40

Technical Indicators

Market Signals
Indicator
LPA
KZIA
Relative Strength Index (RSI) 41.37 41.11
Support Level $2.84 $5.71
Resistance Level $3.33 $14.57
Average True Range (ATR) 0.18 1.07
MACD -0.03 -0.36
Stochastic Oscillator 29.05 11.06

Price Performance

Historical Comparison
LPA
KZIA

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: